Tavros and Vividion collaborate to define novel oncology drug targets and biomarkers
Oct. 13, 2022
Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.